
The State of Arkansas has filed a complaint against Novo Nordisk, Eli Lilly, and Sanofi – all makers of the insulin supplying the state – as well as a group of pharmacy benefit managers (PBMs) that dominate the insulin pricing system there, including Express Scripts, which is the biggest PBM in the US.
According to Endpoints News, Arkansas Attorney General Leslie Rutledge is claiming that these two groups have devised a scheme where the insulin makers raise their drug prices artificially and then pay some of the profits to the PBMs in rebates.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app